NASDAQ
27.92USD
+1.21 (+4.53%)
We have scored 3 news catalysts on Lakefront Biotherapeutics N.V. (LKFT) over the past 12 months. The biggest single-day move next to one of them came Sep 16, 2026, when LKFT closed +4.5%: “Lakefront Biotherapeutics NV (LKFT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript”. Coverage across the window leans positive (average ticker sentiment +0.10). Most of the impact sits in short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.8B
P/E
—
EPS
—
Beta
0.12
52W range
25.68-37.78
Day range
26.63–28.07
Open
26.71
Prev close
26.71
Volume
890.4K
Avg volume
199.7K
Dividend
0.00
IPO
2005-05-05
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Lakefront Biotherapeutics N.V. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LKFT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
